JIANGSU RECBIO TECHNOLOGY CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.52 CNY | -5.33% |
|
-5.23% | -21.55% |
ETFs positioned on Jiangsu Recbio Technology Co., Ltd.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.05% | 4 M€ | -27.92% |
Jiangsu Recbio Technology Co Ltd is a China-based company mainly engaged in the research and development of vaccines. The Company has a portfolio of clinical-stage and pre-clinical stage vaccines, and its human papilloma virus (HPV) vaccine pipelines comprise of recombinant HPV 9-valent vaccine REC603, recombinant HPV 9-valent vaccines REC601 and REC602, recombinant HPV quadrivalent vaccine REC604a, and recombinant HPV 9-valent vaccine REC604b. The Company also involves in the development of Covid-19 vaccines. The Company mainly distributes products within domestic market.
Sector
Pharmaceuticals
Calendar
2024-08-22
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
7.903
CNY
Average target price
11.99
CNY
Spread / Average Target
+51.67%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -21.55% | 552M | |
| -2.65% | 90.28B | |
| -1.97% | 39.5B | |
| -15.47% | 31.71B | |
| +61.28% | 26.41B | |
| -22.81% | 14.34B | |
| -8.82% | 12.89B | |
| -11.77% | 11.8B | |
| -45.97% | 10.95B | |
| +3.30% | 8.85B |
- Stock Market
- Equities
- 2179 Stock
- Funds and ETFs Jiangsu Recbio Technology Co., Ltd.
